The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:661826839505004bd11dce85a9b4e52a]
Active study medication: 100 mg loading dose; 6 mg maintenance dose per day
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks [clinicaltrials_resource:661826839505004bd11dce85a9b4e52a]
Active study medication: 100 mg loading dose; 6 mg maintenance dose per day
Bio2RDF identifier
661826839505004bd11dce85a9b4e52a
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:661826839505004bd11dce85a9b4e52a
measure [clinicaltrials_vocabulary:measure]
The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb)
time frame [clinicaltrials_vocabulary:time-frame]
description
Active study medication: 100 mg loading dose; 6 mg maintenance dose per day
identifier
clinicaltrials_resource:661826839505004bd11dce85a9b4e52a
title
The primary efficacy endpoint was the change from Baseline in hemoglobin (Hb) 12 Weeks
@en
type
label
The primary efficacy endpoint ...... 826839505004bd11dce85a9b4e52a]
@en